Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Milsom I, Abrams P, Cardozo L, et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001, 87:760–766.
2. Stewart W, Herzog R, Wein A, et al.: The NOBLE Program Research Team: prevalence and impact of overactive bladder in the US: Results from the NOBLE program. Neurourol Urodyn 2001, 20:403–422.
3. Igawa Y: Discussion: functional role of M1, M2, and M3 muscarinic receptors in overactive bladder. Urology 2000, 55(suppl 5A):47–49. Provides data on muscarinic receptor research and discusses the significance of receptor subtypes and effects on OAB pharmacotherapy.
4. Schwantes U, Topfmeier P: Importance of pharmacological and physiochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia: chances for improvement of therapy. Int J Clin Pharmacol Ther 1999, 37:209–218. Reviews and highlights the importance of chemical structure in kinetic and dynamic properties.
5. Dmochowski RR, Appell RA: Advancements in pharmacologic management of the overactive bladder. Urology 2000, 56(suppl 6A):41–49. Cutting-edge analysis of pharmacologic therapy by leading minds in the field of urology.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献